Browse the evidence

For patients with Class II obesity (BMI 35-39.9 kg/m2), tirzepatide is significantly superior to other medications and endoscopic procedures, but its weight loss efficacy is inferior to major surgeries like Roux-en-Y gastric bypass (RYGB) and One-Anastomosis Gastric Bypass (OAGB).

If you have Class II obesity (BMI 35-39.9), surgery (like gastric bypass) will likely help you lose more weight than medication. However, if you are not ready for or cannot undergo surgery, newer medications like tirzepatide are still significantly more effective than other non-surgical options, though they will not achieve the same level of weight loss as surgery.

Once-weekly subcutaneous semaglutide at 2.4 mg significantly improves heart failure symptoms, exercise capacity, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, independent of weight loss mechanisms.

For patients with HFpEF and obesity, once-weekly semaglutide (2.4 mg) significantly improves heart failure symptoms, exercise capacity, and quality of life. This treatment addresses a major unmet need in this population, offering benefits beyond weight loss alone. Patients should discuss this option with their healthcare provider, considering the potential for gastrointestinal side effects and the significant clinical improvements observed.

Intensive glycemic control (targeting HbA1c ≤ 7%) significantly reduces cardiovascular events and microvascular complications in patients with Type 1 Diabetes.

If you have Type 1 Diabetes, keeping your blood sugar as close to normal as possible (targeting an A1c around 7%) is proven to significantly lower your risk of heart disease and kidney/eye damage over the long term.

Statins significantly reduce cardiovascular events, all-cause mortality, and stroke in patients with Type 2 Diabetes, regardless of baseline cholesterol levels.

If you have Type 2 Diabetes, taking a statin (like atorvastatin) is a highly effective way to prevent heart attacks, strokes, and early death, even if your cholesterol numbers aren't extremely high.

SGLT2 inhibitors (specifically empagliflozin) reduce major adverse cardiovascular events (MACE) and cardiovascular death in patients with Type 2 Diabetes and established cardiovascular disease.

If you have Type 2 Diabetes and established cardiovascular disease, empagliflozin (10 or 25 mg daily) can significantly reduce your risk of major cardiovascular events and cardiovascular death. This benefit is observed even in patients with moderately reduced kidney function (eGFR > 30). The mechanism is likely related to hemodynamic changes rather than just glucose lowering.

GLP-1 receptor agonists (GLP-1RA) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardiovascular and renal benefits in T2D patients, whereas sulphonyureas are associated with increased cardiovascular mortality.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about GLP-1RA or SGLT2i medications, as they protect your heart and kidneys. Avoid sulphonyureas if possible, as they may increase cardiovascular risk.

Excess body fat during childhood and adolescence causally increases the risk of developing Polycystic Ovary Syndrome (PCOS) in adulthood, independent of adult body size.

Maintaining healthy body composition during childhood and adolescence is critical for preventing PCOS later in life. Even if adult weight is normal, excess fat during youth leaves a lasting metabolic imprint (insulin resistance/low SHBG) that increases PCOS risk. Early lifestyle interventions are the most effective prevention strategy.

Lifestyle interventions for obesity typically result in modest long-term weight loss (5-10%) and high rates of weight regain due to potent biological adaptations, specifically increased appetite and reduced energy expenditure.

If you lose weight through diet and exercise, expect your body to fight back with increased hunger and a slower metabolism. This is a normal biological response, not a failure of willpower. To maintain loss, you may need ongoing support or pharmacological intervention to counteract these specific hormonal signals.

Obesity significantly increases the risk of cardiovascular diseases (CVDs), including hypertension, coronary artery disease, heart failure, and arrhythmias, through mechanisms involving inflammation, endothelial dysfunction, and cardiac structural changes.

If you have obesity, you are at a significantly higher risk for heart disease, high blood pressure, and heart failure. This risk is driven by inflammation and structural changes in the heart. Weight loss through lifestyle changes is crucial for managing these risks. Regular screening for blood pressure, cholesterol, and heart function is recommended.

Obesity is a major risk factor for various cancers, including endometrial, ovarian, prostate, colorectal, pancreatic, liver, gallbladder, kidney, thyroid, and meningioma, as well as hematological malignancies like multiple myeloma and leukemia.

Maintaining a healthy weight reduces your risk of developing several types of cancer, including colorectal, kidney, and endometrial cancer. Weight management through lifestyle changes is a key preventive strategy.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and tirzepatide reduce body weight primarily by suppressing energy intake through activation of GLP-1 receptors in the central nervous system (CNS) and peripheral vagal afferent pathways, rather than by increasing energy expenditure.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, primarily by reducing appetite and food intake through brain and gut signaling. They are taken once weekly. While they achieve significant weight loss (15-20%+ in trials), real-world results vary, and about a third of users may not lose enough weight to be clinically effective. Common side effects like nausea are frequent but often manageable with dose titration. These drugs are not a magic bullet for everyone, especially those with type 2 diabetes or lower starting weights, and require medical supervision.

Semaglutide (1.0 mg/week) significantly reduces major kidney disease events, slows eGFR decline, and lowers MACE risk in patients with type 2 diabetes and chronic kidney disease.

If you have type 2 diabetes and kidney disease, semaglutide (1 mg weekly) is a proven treatment to protect your kidneys from failing and reduce your risk of heart events. It is taken as a weekly injection, starting at a low dose to minimize side effects, and works alongside your current blood pressure medications.

Tirzepatide (up to 15 mg/week) reduces the risk of worsening heart failure and cardiovascular death in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

If you have heart failure with preserved ejection fraction and obesity, tirzepatide (up to 15 mg weekly) can help reduce your risk of heart failure worsening and cardiovascular death. It is taken as a weekly injection, escalated to the maximum tolerated dose.

GLP-1RAs confer cardiovascular protection by reducing the risk of major adverse cardiovascular events (MACE), including death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke, particularly in patients with established cardiovascular disease and obesity.

If you have obesity and existing heart disease, GLP-1 receptor agonists like semaglutide can significantly reduce your risk of heart attack, stroke, and cardiovascular death. This benefit is independent of whether you have diabetes, making these medications a crucial part of cardiovascular risk management for obese patients.

Gastrointestinal adverse events (nausea, vomiting, diarrhea) associated with once-weekly semaglutide 2.4 mg are transient, mild-to-moderate, and contribute negligibly (<1 percentage point) to the total weight loss achieved.

If you are prescribed once-weekly semaglutide 2.4 mg, expect gastrointestinal side effects like nausea or diarrhea, especially when starting or increasing the dose. These symptoms are typically mild, temporary, and resolve on their own. Crucially, do not assume these side effects are necessary for the drug to work; the medication causes weight loss primarily by regulating appetite and satiety, not by making you sick. Most patients tolerate the medication well enough to stay on the full dose.

GLP-1 receptor agonists (GLP-1RAs) reduce body weight primarily by suppressing food intake through central nervous system mechanisms, including hypothalamic and hindbrain signaling and vagal afferent stimulation.

GLP-1 medications like semaglutide and liraglutide help you lose weight by signaling your brain to feel full and eat less, rather than by burning more calories. This effect is driven by the drug acting on satiety centers in the brain and vagus nerve. While side effects like nausea are common initially, they often subside over time. Consistent use is required to maintain weight loss, as stopping the medication typically leads to weight regain.

GLP-1 receptor agonists reduce cardiovascular risk (MACE) and improve renal outcomes in patients with Type 2 Diabetes, independent of weight loss.

For patients with Type 2 Diabetes, especially those with heart disease or kidney risks, GLP-1 medications offer significant protection against heart attacks, strokes, and kidney failure. These benefits are independent of weight loss and are supported by extensive clinical trial data. The choice between daily injections, weekly injections, or oral tablets depends on patient preference and tolerance.

Metformin provides modest weight loss (average ~2.1 kg/year) and improves insulin sensitivity, making it a first-line treatment for T2DM, though it is not FDA-approved specifically for weight loss.

Metformin is a standard first-line medication for Type 2 Diabetes. It helps control blood sugar and may lead to modest weight loss (about 2 kg per year), but it is not a powerful weight-loss drug. It is generally safe and well-tolerated, though some people experience gastrointestinal side effects.

GLP-1 receptor agonists (e.g., semaglutide) and GLP-2 analogs (e.g., teduglutide) are FDA-approved interventions that treat obesity and short bowel syndrome by mimicking enteroendocrine cell hormone secretion.

If you have obesity or short bowel syndrome, talk to your doctor about GLP-1 based medications like semaglutide. These are FDA-approved treatments that mimic your gut's natural hormones to help with weight loss or nutrient absorption. They are not lifestyle fixes but medical interventions for specific conditions.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) provide cardiovascular and kidney protection in patients with chronic kidney disease (CKD) and overweight/obesity, with or without type 2 diabetes (T2DM), by reducing major adverse cardiovascular events (MACE) and slowing kidney disease progression.

If you have chronic kidney disease and are overweight or obese, ask your doctor about GLP-1 receptor agonists like semaglutide or liraglutide. These medications are not just for weight loss; they have been proven to protect your heart and kidneys, even if you do not have diabetes. They are available in both daily and weekly formulations, and sometimes orally, making them a versatile option for managing your overall metabolic health.

Liraglutide 1.8 mg/day reduces the risk of major adverse cardiovascular events (MACE), cardiovascular death, and all-cause mortality in patients with Type 2 Diabetes and high cardiovascular risk.

If you have Type 2 Diabetes and are at high risk for heart problems, adding a daily 1.8 mg liraglutide injection can significantly lower your risk of heart attack, stroke, and death from cardiovascular causes, without increasing the risk of heart failure hospitalization.

Semaglutide (2.4 mg weekly) produces a clinically significant reduction in systolic blood pressure (approx. 4.8 mmHg) and diastolic blood pressure (approx. 2.5 mmHg) in adults with obesity but without diabetes, even among those with normotensive baseline blood pressure.

If you have obesity and high blood pressure (or even normal blood pressure), semaglutide 2.4 mg taken once weekly can significantly lower your blood pressure. This benefit exists even if you are not currently diagnosed with hypertension. It is a weight-centric approach to managing blood pressure.

Insulin therapy is associated with significant weight gain (mean 4.3 kg) in patients with Type 2 Diabetes, driven by caloric conservation, anabolic effects, and defensive eating to avoid hypoglycemia.

If you are on insulin and gaining weight, know that this is a known side effect caused by how insulin stores energy and your body's response to prevent low blood sugar. Discuss switching to or adding GLP-1 agonists with your doctor, as they can help with weight loss while managing blood sugar.

A 12-week treatment with dulaglutide prevents post-cessation weight gain in the short term (12 weeks), but this benefit is lost after discontinuation, resulting in similar weight gain to placebo at 52 weeks.

Dulaglutide can help you avoid gaining weight during your first 12 weeks of quitting smoking. However, once you stop the injections, you will likely gain weight similar to someone not taking the drug. To maintain weight loss, you may need to stay on the medication longer than 12 weeks.